A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, redu
A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
대표청구항▼
1. An anti-adhesion product in the form of a plaster or sponge, said product comprising a biocompatible modified starch, wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units contained in the starch, wherein the product forms an adhesion barrier in
1. An anti-adhesion product in the form of a plaster or sponge, said product comprising a biocompatible modified starch, wherein the biocompatible modified starch is modified by carboxylation or hydroxylation of glucose units contained in the starch, wherein the product forms an adhesion barrier in the form of a starch-blood coagulation matrix upon contacting a wound tissue. 2. The anti-adhesion product of claim 1, wherein the biocompatible modified starch exhibits a water absorbency capacity that is at least 1 times its own weight. 3. The anti-adhesion product of claim 1, wherein the biocompatible modified starch exhibits a water absorbency capacity that is 2-500 times its own weight. 4. The anti-adhesion product of claim 1, wherein the biocompatible modified starch exhibits a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 5. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is degradable by amylase. 6. The anti-adhesion product of claim 1, wherein the anti-adhesion product is free of polyethylene glycol. 7. The anti-adhesion product of claim 1, wherein the biocompatible modified starch contains a modified glucose unit of the formula: 8. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is carboxymethyl starch. 9. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is hydroxyethyl starch. 10. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is cross-linked. 11. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is not cross-linked. 12. The anti-adhesion product of claim 1, wherein the biocompatible modified starch exhibits a molecular weight of at least 15,000 daltons. 13. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is pre-gelatinized modified starch. 14. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is composite modified starch. 15. The anti-adhesion product of claim 1, wherein the biocompatible modified starch is non-porous.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (27)
Ganslaw ; Stuart H. ; Katz ; Howard G., Absorbent composition of matter.
Kwon Sang Gi,KRX ; Cho Yang Rae,KRX ; Park Chan Hun,KRX ; Ko Chul Jong,KRX, Carboxymethyl-etherified starch derivatives and process for preparing the same.
Jy, Wenche; Jimenez, Joaquin J.; Horstmann, Lawrence L.; Ahn, Yeon S.; Ahn, Eugene, Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders.
Errede Louis A. (North Oaks MN) Stoesz James D. (St. Paul MN) Winter ; deceased George D. (late of St. Paul MN by Jenny Upton ; personal representative), Composite wound dressing.
Abe,Yoshihiko; Anzai,Takao, Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition, and medical treatment material.
de Belder Anthony N. (Uppsala SEX) Mlson Thomas (Uppsala SEX), Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said m.
Barrington James E. (Woburn MA) Williams David L. (Reading MA) Hitchcock Charles J. (Cambridge MA) Mullins Thomas J. (Woburn MA), Powder blower device.
Terakura Seiji (Ikoma JPX) Maeda Toyoyuki (Kawachinagano JPX), Powdered medicament-mixed gas injecting apparatus and powdered medicament-mixed gas injecting nozzle to be connected to.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.